Loading
Adding the kinase inhibitor sorafenib to chemotherapy improved event-free survival in children with high allelic ratio FLT3-ITD acute myeloid leukaemia compared with matched historical controls, the first FLT3-targeted result in paediatric leukaemia.
Non-randomised cohort within the AAML1031 trial of 92 children with high allelic ratio FLT3-ITD AML treated with sorafenib during induction, consolidation and maintenance, compared with 76 concurrent and historical controls treated without sorafenib.
Three-year event-free survival was 55.9 versus 31.9 percent and relapse risk lower with sorafenib; benefit was concentrated in patients who received it from the first induction course, and toxicity was mostly rash and hand-foot syndrome.
FLT3 inhibitors are now incorporated into frontline paediatric AML therapy for FLT3-ITD, with gilteritinib being studied in the successor trial.
Shares Acute myeloid leukaemia in children, Journal of Clinical Oncology.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/